BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data In Phase III Program

[News]

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study...

More... (http://mnt.to/f/3y3h)